



FOR IMMEDIATE RELEASE

AGM Update

SYDNEY, AUSTRALIA – 17 November 2009 – NuSep (ASX: NSP) wishes to announce that following on from discussions with ASIC, the Board has decided to withdraw resolutions 4 to 12 from consideration by shareholders at the Annual General Meeting of NuSep scheduled to take place on Monday, 30 November 2009.

Accordingly, shareholders should disregard information in relation to resolutions 4 to 12 that was disclosed by NuSep in the Explanatory Statement that accompanied the Notice of Meeting for the Annual General Meeting.

NuSep will re-submit resolutions 4 to 12 to the shareholders for consideration at a general meeting to be convened early in the 2010 calendar year.

As announced previously, the AGM will be held on Monday 30 November at 10am at NuSep's Sydney offices at 324 Burns Bay Road, Lane Cove, NSW. As part of this meeting the Board will update shareholders on recent developments and the Company's forward projections.

A visit to the manufacturing and laboratory facilities will follow the meeting. We encourage all shareholders to attend.

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global bioseparations market. The company has offices in both Sydney, Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world's first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep's world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:


-  **Gels** – NuSep manufactures and sells precast gels including the innovative iGels, with a 2 year shelf life.
-  **Separation Instruments** – NuSep has developed two unique biological separation instruments. The first instrument released in 2008 can separate biological samples into 8 fractions for use in the proteomic market. The second instrument (SpermSep) separates sperm for fertility treatments such as IVF. Initial successful clinical trials were completed in late 2008 and final clinical trials will be undertaken in 2010 with sales to occur later that year.

NuSep Ltd
324 Burns Bay Rd
Lane Cove NSW 2066

Postal Address
P.O. Box 823
Lane Cove NSW 1595

Contact Details
Telephone +61 2 9427 8384
Facsimile +61 2 9427 8614

Email info@nusep.com
Web www.nusep.com
ABN 33 120 047 556

 **Biological Products** – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.

For more information about NuSep please visit the company's website www.NuSep.com

Contact:
Prakash Patel
Chief Financial Officer & Company Secretary
+61 2 9420 8384
prakash.patel@nusep.com